Kimia Biosciences Management

Management criteria checks 3/4

Kimia Biosciences' CEO is Sameer Goel, appointed in May 2022, has a tenure of 8.17 years. directly owns 74.94% of the company’s shares, worth ₹1.78B. The average tenure of the management team and the board of directors is 2 years and 8.1 years respectively.

Key information

Sameer Goel

Chief executive officer

₹6.0m

Total compensation

CEO salary percentage	n/a
CEO tenure	2yrs
CEO ownership	74.9%
Management average tenure	2yrs
Board average tenure	8.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Sameer Goel's remuneration changed compared to Kimia Biosciences's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-₹133m
Sep 30 2023	n/a	n/a	-₹148m
Jun 30 2023	n/a	n/a	-₹132m
Mar 31 2023	₹6m	n/a	-₹94m
Dec 31 2022	n/a	n/a	-₹46m
Sep 30 2022	n/a	n/a	-₹25m
Jun 30 2022	n/a	n/a	-₹29m
Mar 31 2022	₹6m	n/a	-₹37m
Dec 31 2021	n/a	n/a	-₹32m
Sep 30 2021	n/a	n/a	-₹14m
Jun 30 2021	n/a	n/a	₹34m
Mar 31 2021	n/a	n/a	₹51m
Dec 31 2020	n/a	n/a	₹52m
Sep 30 2020	n/a	n/a	₹49m
Jun 30 2020	n/a	n/a	₹30m
Mar 31 2020	₹444k	₹444k	₹14m
Dec 31 2019	n/a	n/a	₹21m
Sep 30 2019	n/a	n/a	₹40m
Jun 30 2019	n/a	n/a	₹38m
Mar 31 2019	₹5m	₹5m	₹39m

Compensation vs Market: Sameer's total compensation ($USD71.87K) is above average for companies of similar size in the Indian market ($USD39.44K).

Compensation vs Earnings: Sameer's compensation has been consistent with company performance over the past year.

CEO

Sameer Goel (48 yo)

2yrs

Tenure

₹6,000,000

Compensation

Mr. Sameer Goel has been Chief Executive Officer of Kimia Biosciences Limited since May 30, 2022. He serves as Managing Director of KIMIA Biosciences Pvt. Ltd.Mr. Goel has been the Chairman, Managing Dire...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Sameer Goel	CEO, Chairman of the Board & MD	2yrs	₹6.00m	74.94% ₹ 1.8b
Rakesh Chetani	Chief Financial Officer	less than a year	no data	no data
Subrat Satpathy	Chief Operating Officer	2.7yrs	₹6.55m	no data
Mathura Joshi	Assistant General Manager of Finance & Accounts	no data	no data	no data
Lakshay Prakash	Company Secretary & Compliance Officer	2yrs	no data	no data
Ruchita Mishra	Manager of Marketing	no data	no data	no data
Asit Bhalerao	Chief Human Resources Officer	2.5yrs	₹7.00m	no data
Mukesh Sharma	Head of Research & Development	no data	₹3.59m	no data
Rita Sarin	Advisor of Strategy & IPR Head of Intellectual Property Rights	no data	no data	no data

2.0yrs

Average Tenure

48yo

Average Age

Experienced Management: 530313's management team is considered experienced (2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Sameer Goel	CEO, Chairman of the Board & MD	8.2yrs	₹6.00m	74.94% ₹ 1.8b
Jagdeep Dhawan	Independent Non-Executive Director	8.2yrs	no data	no data
Richa Gupta	Independent Non-Executive Woman Director	8.1yrs	no data	no data
Vipul Goel	Non-Executive Non Independent Director	5.4yrs	no data	0.000030% ₹ 714.1

8.1yrs

Average Tenure

46.5yo

Average Age

Experienced Board: 530313's board of directors are considered experienced (8.1 years average tenure).

Kimia Biosciences Management

Management criteria checks 3/4

Key information

Recent management updates

Insufficient new directors

Kimia Biosciences Limited Announces Chief Financial Officer Changes

Kimia Biosciences Limited, Annual General Meeting, Sep 30, 2023

Kimia Biosciences Limited Announces Appointment of Ms. Mita Namonath Jha as an Additional Director (Non-Executive and Non-Independent Director )

Insufficient new directors

Kimia Biosciences Limited, Annual General Meeting, Sep 30, 2022

Recent updates

Insufficient new directors

New minor risk - Share price stability

Third quarter 2024 earnings released: ₹0.41 loss per share (vs ₹0.98 loss in 3Q 2023)

Kimia Biosciences Limited to Report Q3, 2024 Results on Feb 14, 2024

Second quarter 2024 earnings released: ₹0.52 loss per share (vs ₹0.18 loss in 2Q 2023)

Kimia Biosciences Limited to Report Q4, 2025 Results on May 30, 2025

Kimia Biosciences Limited Announces Chief Financial Officer Changes

Kimia Biosciences Limited, Annual General Meeting, Sep 30, 2023

Kimia Biosciences Limited Announces Appointment of Ms. Mita Namonath Jha as an Additional Director (Non-Executive and Non-Independent Director )

First quarter 2024 earnings released: ₹0.57 loss per share (vs ₹0.23 profit in 1Q 2023)

Full year 2023 earnings released: ₹1.98 loss per share (vs ₹0.78 loss in FY 2022)

Insufficient new directors

Kimia Biosciences Limited to Report First Half, 2023 Results on Nov 14, 2022

Kimia Biosciences Limited to Report Q4, 2023 Results on Apr 12, 2023

Kimia Biosciences Limited, Annual General Meeting, Sep 30, 2022

Kimia Biosciences Limited, Annual General Meeting, Sep 30, 2022

First quarter 2023 earnings released: EPS: ₹0.23 (vs ₹0.07 in 1Q 2022)

Full year 2022 earnings released: ₹0.78 loss per share (vs ₹1.08 profit in FY 2021)

Kimia Biosciences Limited Appoints Sameer Goel as Chief Executive Officer

Kimia Biosciences Limited Announces Resignation of Suneel Kapoor as Chief Executive Officer

Kimia Biosciences Limited Announces Granted Permission to Manufacture and Marketing of Bemopedoic Acid Bulk Drug Under New Drug and Clincial Trials

Kimia Biosciences Limited Announces Appointment of Lakshay Prakash as Company Secretary

Insufficient new directors

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Kimia Biosciences Limited to Report Q3, 2022 Results on Feb 14, 2022

Insufficient new directors

Company Secretary & Compliance Officer Abhishek Pandey has left the company

First quarter 2022 earnings released: EPS ₹0.07 (vs ₹0.43 in 1Q 2021)

Full year 2021 earnings released: EPS ₹1.08 (vs ₹0.33 in FY 2020)

Investor sentiment improved over the past week

Kimia Biosciences Limited Bags Permission to Manufacture Bilastine API New Active Pharmaceutical Ingredient for Sale or for Distribution

Kimia Biosciences Limited Receives Permission to Manufacture New Active Pharmaceutical Ingredient for Sale or for Distribution

New 90-day low: ₹40.75

Third quarter 2021 earnings released: EPS ₹0.09 (vs ₹0.03 in 3Q 2020)

Kimia Biosciences Limited to Report Q3, 2021 Results on Feb 11, 2021

Investor sentiment improved over the past week

New 90-day high: ₹50.80

New 90-day high: ₹44.95

Market bids up stock over the past week

Market bids up stock over the past week

Kimia Biosciences Limited to Report Q2, 2021 Results on Nov 05, 2020

Kimia Biosciences Limited Approves Appointment of Vipul Goel as Non Executive, Non Independent Director

First quarter earnings released

New 90-day high - ₹33.80

Kimia Biosciences Limited to Report Q1, 2021 Results on Aug 18, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age